User login
Key clinical point: Management of multiple sclerosis relapse consists of three main steps: timely and careful evaluation; treatment, if necessary; and assessment of treatment response, according to an algorithm developed by MS clinicians.
Major finding: Between 3 and 5 weeks after the initial evaluation, the group recommends clinical reassessment using a tool such as the Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire.
Study details: A consensus statement developed by a work group of MS clinicians based on a literature review and clinical experience.
Disclosures: The work group did not receive funding. The authors disclosed financial ties with various pharmaceutical companies.
Citation: REPORTING FROM CMSC 2019
Key clinical point: Management of multiple sclerosis relapse consists of three main steps: timely and careful evaluation; treatment, if necessary; and assessment of treatment response, according to an algorithm developed by MS clinicians.
Major finding: Between 3 and 5 weeks after the initial evaluation, the group recommends clinical reassessment using a tool such as the Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire.
Study details: A consensus statement developed by a work group of MS clinicians based on a literature review and clinical experience.
Disclosures: The work group did not receive funding. The authors disclosed financial ties with various pharmaceutical companies.
Citation: REPORTING FROM CMSC 2019
Key clinical point: Management of multiple sclerosis relapse consists of three main steps: timely and careful evaluation; treatment, if necessary; and assessment of treatment response, according to an algorithm developed by MS clinicians.
Major finding: Between 3 and 5 weeks after the initial evaluation, the group recommends clinical reassessment using a tool such as the Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire.
Study details: A consensus statement developed by a work group of MS clinicians based on a literature review and clinical experience.
Disclosures: The work group did not receive funding. The authors disclosed financial ties with various pharmaceutical companies.
Citation: REPORTING FROM CMSC 2019